192 related articles for article (PubMed ID: 17965864)
21. Recent progress in the treatment of lupus nephritis.
Fanouriakis A; Krasoudaki E; Tzanakakis M; Boumpas DT
Mod Rheumatol; 2012 Nov; 22(6):803-13. PubMed ID: 22584472
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis.
Karassa FB; Isenberg DA
N Engl J Med; 2001 Feb; 344(5):382-3. PubMed ID: 11195799
[No Abstract] [Full Text] [Related]
23. Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?
Belmont HM
Curr Rheumatol Rep; 1999 Dec; 1(2):87-8. PubMed ID: 11123020
[No Abstract] [Full Text] [Related]
24. [Pharmacotherapy of SLE].
Nakazawa T; Kumagai S; Kogata Y
Nihon Rinsho; 2005 May; 63 Suppl 5():253-9. PubMed ID: 15954358
[No Abstract] [Full Text] [Related]
25. Summaries for patients. Multitarget therapy for induction treatment of lupus nephritis.
Ann Intern Med; 2015 Jan; 162(1):I24. PubMed ID: 25383607
[No Abstract] [Full Text] [Related]
26. Nephroquiz 1: cyclophosphamide or mycofenolate mofetil?
Samadian F; Parvin M; Faraji A; Ahmadpoor P
Iran J Kidney Dis; 2009 Apr; 3(2):112-3. PubMed ID: 19395789
[No Abstract] [Full Text] [Related]
27. Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.
Killen JP
N Engl J Med; 2006 Feb; 354(7):764-5; author reply 764-5. PubMed ID: 16482673
[No Abstract] [Full Text] [Related]
28. Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.
Karassa FB
N Engl J Med; 2006 Feb; 354(7):764-5; author reply 764-5. PubMed ID: 16481648
[No Abstract] [Full Text] [Related]
29. What is the ideal duration of maintenance therapy for lupus nephritis?
Yap DYH; Chan TM
Expert Rev Clin Immunol; 2022 May; 18(5):425-427. PubMed ID: 35306959
[No Abstract] [Full Text] [Related]
30. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
[TBL] [Abstract][Full Text] [Related]
31. [Mycophenolate mofetil seems to be superior to azothioprine in maintenance therapy of lupus nephritis].
Schmalzing M; Kötter I
Z Rheumatol; 2012 Nov; 71(9):813-5. PubMed ID: 22926540
[No Abstract] [Full Text] [Related]
32. Toward better treatment for lupus nephritis.
Houssiau FA
N Engl J Med; 2011 Nov; 365(20):1929-30. PubMed ID: 22087685
[No Abstract] [Full Text] [Related]
33. [Lupus nephritis, mycophenolate, and cytomegalovirus infection].
Sánchez de la Nieta MD; Carreño A; de la Torre M; Rivera F
Nefrologia; 2006; 26(1):141-2. PubMed ID: 16649438
[No Abstract] [Full Text] [Related]
34. Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen.
Tedeschi B; Arnaud L; Hie M; Mathian A; Amoura Z
Ann Rheum Dis; 2014 Feb; 73(2):474-5. PubMed ID: 24001887
[No Abstract] [Full Text] [Related]
35. Lupus nephritis: keeping the wolf at bay.
Radhakrishnan J
Clin J Am Soc Nephrol; 2013 Jan; 8(1):136-7. PubMed ID: 23296379
[No Abstract] [Full Text] [Related]
36. Lupus nephritis: guidelines for lupus nephritis--more recommendations than data?
Rovin BH
Nat Rev Nephrol; 2012 Nov; 8(11):620-1. PubMed ID: 23007619
[No Abstract] [Full Text] [Related]
37. Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide.
Elliott JR; Manzi S
Nat Clin Pract Rheumatol; 2006 Jul; 2(7):354-5. PubMed ID: 16932717
[No Abstract] [Full Text] [Related]
38. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
[TBL] [Abstract][Full Text] [Related]
39. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
Bertsias GK; Tektonidou M; Amoura Z; Aringer M; Bajema I; Berden JH; Boletis J; Cervera R; Dörner T; Doria A; Ferrario F; Floege J; Houssiau FA; Ioannidis JP; Isenberg DA; Kallenberg CG; Lightstone L; Marks SD; Martini A; Moroni G; Neumann I; Praga M; Schneider M; Starra A; Tesar V; Vasconcelos C; van Vollenhoven RF; Zakharova H; Haubitz M; Gordon C; Jayne D; Boumpas DT;
Ann Rheum Dis; 2012 Nov; 71(11):1771-82. PubMed ID: 22851469
[TBL] [Abstract][Full Text] [Related]
40. Lupus nephritis: MAINTAINing perspective in lupus nephritis trials.
Rovin BH; Ayoub I
Nat Rev Nephrol; 2015 Jul; 11(7):389-90. PubMed ID: 25917554
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
